Mirati Therapeutics, Inc.
9363 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
Phone: 858-332-3410
Website:
http://www.mirati.com
Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of products targeting oncology. Its clinical stage product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase 1b clinical development trials for the treatment of solid tumors indications, including lung, head and neck, and gastric cancers; MGCD516, a kinase inhibitor, which is in Phase 1 clinical development for the treatment of patients with non-small cell lung cancer and solid tumors; and Mocetinostat, an orally-bioavailable histone deacetylase inhibitor that is in Phase 2 clinical trial development for patients with bladder cancer, myelodysplastic syndrome, and non-hodgkins lymphoma, principally diffuse large B-cell lymphoma and follicular lymphoma. The company has a collaboration agreement with MedImmune Limited for a trial of a combination of inhibitors for the treatment of non-small cell lung cancer. Mirati Therapeutics, Inc. is headquartered in San Diego, California.